NCT07155252 Home-based Oral Glucose Tolerance Test for Type 1 Diabetes Screening
| NCT ID | NCT07155252 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yale University |
| Condition | Type 1 Diabetes |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-08-26 |
| Primary Completion | 2027-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 60 participants in total. It began in 2025-08-26 with a primary completion date of 2027-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims at quantifying the accuracy of a self-administered fingerstick based glucose tolerance test (GTT@Home) respect to the gold-standard in-clinic venous plasma measures during the oral glucose tolerance test (OGTT) across a wide range of glycemic values in people at risk for clinical type 1 diabetes (T1D) (carriers of at least one islet autoantibody) or with new onset Stage 3 T1D within 100 days from the diagnosis.
Eligibility Criteria
Inclusion Criteria: * Body weight ≥43 kg * Presence of at least one islet autoantibody and/or≥ diagnosis of clinical T1D within 100 days. * Documentation of the presence at least 1 islet autoantibody * If participants meet ADA diagnostic criteria for Stage 3 type 1 diabetes, they will be eligible if the enrollment occurs within 100 days from the diagnosis and are at least 12 years old. * Participants must be in good general health without other acute (e.g. infectious disease) febrile or chronic illnesses (e.g. uncontrolled asthma requiring high steroid doses, chronic arthritis) that in the judgment of the investigator could jeopardize participant safety or interfere with the study, * Ability to give consent/assent * Able to understand written and spoken English Exclusion Criteria: * Currently pregnant or becomes pregnant during the study * Participants on sodium glucose cotransporter inhibitors (SGLTi). * Donated blood in the past 8 weeks.
Contact & Investigator
Jennifer Sherr, MD
PRINCIPAL INVESTIGATOR
Yale University
Frequently Asked Questions
Who can join the NCT07155252 clinical trial?
This trial is open to participants of all sexes, aged 8 Years or older, up to 45 Years, studying Type 1 Diabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07155252 currently recruiting?
Yes, NCT07155252 is actively recruiting participants. Contact the research team at marcia.desousa@yale.edu for enrollment information.
Where is the NCT07155252 trial being conducted?
This trial is being conducted at New Haven, United States.
Who is sponsoring the NCT07155252 clinical trial?
NCT07155252 is sponsored by Yale University. The principal investigator is Jennifer Sherr, MD at Yale University. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.